Pathological Role of HDAC8: Cancer and Beyond
Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and o...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/19/3161 |
| _version_ | 1827654689895743488 |
|---|---|
| author | Ji Yoon Kim Hayoung Cho Jung Yoo Go Woon Kim Yu Hyun Jeon Sang Wu Lee So Hee Kwon |
| author_facet | Ji Yoon Kim Hayoung Cho Jung Yoo Go Woon Kim Yu Hyun Jeon Sang Wu Lee So Hee Kwon |
| author_sort | Ji Yoon Kim |
| collection | DOAJ |
| description | Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and overexpression of HDAC8 give rise to diseases. HDAC8 is especially involved in various aspects of cancer progression, such as cancer cell proliferation, metastasis, immune evasion, and drug resistance. HDAC8 is also associated with the development of non-cancer diseases such as Cornelia de Lange Syndrome (CdLS), infectious diseases, cardiovascular diseases, pulmonary diseases, and myopathy. Therefore, HDAC8 is an attractive therapeutic target and various HDAC8 selective inhibitors (HDAC8is) have been developed. Here, we address the pathological function of HDAC8 in cancer and other diseases, as well as illustrate several HDAC8is that have shown anti-cancer effects. |
| first_indexed | 2024-03-09T21:52:25Z |
| format | Article |
| id | doaj.art-00d087e8be75476f8796f5f76a5c358d |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T21:52:25Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-00d087e8be75476f8796f5f76a5c358d2023-11-23T20:03:51ZengMDPI AGCells2073-44092022-10-011119316110.3390/cells11193161Pathological Role of HDAC8: Cancer and BeyondJi Yoon Kim0Hayoung Cho1Jung Yoo2Go Woon Kim3Yu Hyun Jeon4Sang Wu Lee5So Hee Kwon6College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, KoreaHistone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and overexpression of HDAC8 give rise to diseases. HDAC8 is especially involved in various aspects of cancer progression, such as cancer cell proliferation, metastasis, immune evasion, and drug resistance. HDAC8 is also associated with the development of non-cancer diseases such as Cornelia de Lange Syndrome (CdLS), infectious diseases, cardiovascular diseases, pulmonary diseases, and myopathy. Therefore, HDAC8 is an attractive therapeutic target and various HDAC8 selective inhibitors (HDAC8is) have been developed. Here, we address the pathological function of HDAC8 in cancer and other diseases, as well as illustrate several HDAC8is that have shown anti-cancer effects.https://www.mdpi.com/2073-4409/11/19/3161HDAC8HDAC8 selective inhibitorsepigeneticscancer |
| spellingShingle | Ji Yoon Kim Hayoung Cho Jung Yoo Go Woon Kim Yu Hyun Jeon Sang Wu Lee So Hee Kwon Pathological Role of HDAC8: Cancer and Beyond Cells HDAC8 HDAC8 selective inhibitors epigenetics cancer |
| title | Pathological Role of HDAC8: Cancer and Beyond |
| title_full | Pathological Role of HDAC8: Cancer and Beyond |
| title_fullStr | Pathological Role of HDAC8: Cancer and Beyond |
| title_full_unstemmed | Pathological Role of HDAC8: Cancer and Beyond |
| title_short | Pathological Role of HDAC8: Cancer and Beyond |
| title_sort | pathological role of hdac8 cancer and beyond |
| topic | HDAC8 HDAC8 selective inhibitors epigenetics cancer |
| url | https://www.mdpi.com/2073-4409/11/19/3161 |
| work_keys_str_mv | AT jiyoonkim pathologicalroleofhdac8cancerandbeyond AT hayoungcho pathologicalroleofhdac8cancerandbeyond AT jungyoo pathologicalroleofhdac8cancerandbeyond AT gowoonkim pathologicalroleofhdac8cancerandbeyond AT yuhyunjeon pathologicalroleofhdac8cancerandbeyond AT sangwulee pathologicalroleofhdac8cancerandbeyond AT soheekwon pathologicalroleofhdac8cancerandbeyond |